SLNO241220P20000
- 0.50
- 0.000.00%
Soleno Therapeutics Newsroom
Baird Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $72
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Soleno Therapeutics Says FDA Extends DCCR NDA Review Citing 'Major Amendment'
Express News | Soleno Therapeutics Shares Slide 13% Premarket After Co Announces US FDA Extension of Review Period for Genetic Disorder Treatment
Soleno Therapeutics Announces U.S.. FDA to Ended Review Period for NDA
Express News | Soleno: FDA Determined That Responses to Recent Information Requests Constituted a Major Amendment to Nda for Dccr Extended-Release Tablets
Express News | Soleno Therapeutics Inc - FDA Did Not Cite Safety, Efficacy or Manufacturing Concerns
Express News | Soleno Therapeutics Inc - New Pdufa Target Action Date Set for March 27, 2025
Soleno Therapeutics Reports Q3 Progress and Financials
Express News | Soleno Therapeutics Announces Oral Presentations Featuring Diazoxide Choline Extended-Release (Dccr) Tablets in Prader-Willi Syndrome at Espe 2024
H.C. Wainwright Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $70
Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation
Positive Outlook for Soleno Therapeutics: Buy Rating Based on Anticipated FDA Approval and Strong Cash Position
Stifel Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $74
Soleno Therapeutics (SLNO) Receives a Buy From Stifel Nicolaus
Cantor Fitzgerald Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $67
Cantor Fitzgerald Remains a Buy on Soleno Therapeutics (SLNO)
Soleno Therapeutics Reports Q3 EPS($1.83) , Consensus (63c)
Soleno Therapeutics | 8-K: Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Soleno Therapeutics | 10-Q: Q3 2024 Earnings Report